MediWound (NASDAQ:MDWD) Shares Cross Above 50 Day Moving Average – Should You Sell?

MediWound Ltd. (NASDAQ:MDWD)’s share price crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $13.05 and traded as high as $13.67. MediWound shares last traded at $13.56, with a volume of 126,554 shares changing hands.

Wall Street Analysts Forecast Growth

A number of research firms have commented on MDWD. Alliance Global Partners reaffirmed a “buy” rating on shares of MediWound in a research report on Wednesday, September 16th. Weiss Ratings downgraded shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. TD Cowen restated a “buy” rating on shares of MediWound in a research report on Thursday, September 24th. Wall Street Zen raised MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, September 26th. Finally, Oppenheimer restated an “outperform” rating and issued a $30.00 price objective (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $33.00.

MediWound Trading Up 8.0%

The firm’s 50-day moving average price is $13.05 and its 200-day moving average price is $15.28. The stock has a market capitalization of $174.27 million, a PE ratio of -7.53 and a beta of 0.09.

MediWound (NASDAQ:MDWD) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The firm had revenue of $3.09 million during the quarter, compared to analysts’ expectations of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. On average, equities research analysts predict that MediWound Ltd. will post -2.37 earnings per share for the current fiscal year.

Insider Buying and Selling at MediWound

In other MediWound news, COO Shmuel Hess sold 3,958 shares of the company’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.20% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds.

MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.